Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Diabetes drug shows promise for heart repair after attack

NCT ID NCT07169981

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 28 times

Summary

This study looked at whether empagliflozin, a medicine already used for diabetes and heart failure, can improve heart structure and function in people with diabetes who had a major heart attack. 200 participants received either 10 mg or 25 mg of the drug and were monitored for 6 months. The goal was to see if the drug could reverse harmful heart changes and improve pumping strength.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ain Shams University Hospitals

    Cairo, Egypt

Conditions

The condition(s) this trial relates to.

diabetes mellitus heart failure ST-elevation myocardial infarction systolic heart failure type 2 diabetes mellitus Ventricular Remodeling

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.